RIGL stock forecast
Our latest prediction for Rigel Pharmaceuticals, Inc.'s stock price was made on the Aug. 17, 2018 when the stock price was at 2.62$.
In the short term (2weeks), RIGL's stock price should outperform the market by 4.99%. During that period the price should oscillate between -8.04% and +12.65%.
In the medium term (3months), RIGL's stock price should outperform the market by 9.26%. During that period the price should oscillate between -18.97% and +36.38%.Get email alerts
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
At the moment the company generates 82M USD in revenues.
On its last earning announcement, the company reported a loss of -0.27$ per share.
The book value per share is 0.74$
Three months stock forecastAug. 17, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|